Publications:
Our Research

A Randomized, Blinded, Controlled, Dose-Ranging Study of a Respiratory Syncytial Virus Recombinant Fusion (F) Nanoparticle Vaccine in Healthy Women of Childbearing Age

Rapid Responses to Novel Lethal Viruses: The Potential of Recombinant Nanoparticle Vaccines Produced in a Baculovirus Insect Cell System

RSV F Nanoparticle Vaccine: Biological Rationale, Summary of the Clinical Data and Path Forward

Recombinant EBOV/Makona Glycoprotein (GP) Nanoparticle Vaccine Produced in Sf9 Insect Cells

Recombinant virus-like particles elicit protective immunity against avian influenza A(H7N9) virus infection in ferrets

EBOV/Makona Glycoprotein (GP) Nanoparticle Vaccine Produced in Sf9 Insect Cells

Rapid Manufacture and Release of a GMP Batch of Zaire Ebolavirus Glycoprotein Vaccine Made Using Recombinant Baculovirus-Sf9 Insect Cell Culture Technology

Recombinant Nanoparticle Vaccine Using Ebola Guinea 2014 GP Sequence

An insect cell derived respiratory syncytial virus (RSV) F nanoparticle vaccine induces antigenic site II antibodies and protects against RSV challenge in cotton rats by active and passive immunization

Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice